Pivotal bioVenture Partners Fund I L.P. 13D and 13G filings for Oculis Holding AG:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-12-09 9:43 pm Purchase |
2024-12-03 | 13G | Oculis Holding AG OCS |
Pivotal bioVenture Partners Fund I L.P. | 2,174,074 5.200% |
141,778 (+6.98%) |
Filing |
| 2024-11-07 4:15 pm Sale |
2024-09-30 | 13G | Oculis Holding AG OCS |
Pivotal bioVenture Partners Fund I L.P. | 2,032,296 4.900% |
-382,676 (-15.85%) |
Filing |
| 2024-02-12 9:06 pm Sale |
2023-12-31 | 13G | Oculis Holding AG OCS |
Pivotal bioVenture Partners Fund I L.P. | 2,414,972 7.400% |
-617,324 (-20.36%) |
Filing |
| 2023-03-15 12:53 pm Purchase |
2023-03-03 | 13G | Oculis Holding AG OCS |
Pivotal bioVenture Partners Fund I L.P. | 3,032,296 9.300% |
3,032,296 (New Position) |
Filing |